Recombinant allergy vaccines based on allergen-derived B cell epitopes.
|
| Abstract |
Immunoglobulin E (IgE)-associated allergy is the most common immunologically-mediated hypersensitivity disease. It affects more than 25% of the population. In IgE-sensitized subjects, allergen encounter can causes a variety of symptoms ranging from hayfever (allergic rhinoconjunctivitis) to asthma, skin inflammation, food allergy and severe life-threatening anaphylactic shock. Allergen-specific immunotherapy (AIT) is based on vaccination with the disease-causing allergens. AIT is an extremely effective, causative and disease-modifying treatment. However, administration of natural allergens can cause severe side effects and the quality of natural allergen extracts limits its application. Research in the field of molecular allergen characterization has allowed deciphering the molecular structures of the disease-causing allergens and it has become possible to engineer novel molecular allergy vaccines which precisely target the mechanisms of the allergic immune response and even appear suitable for prophylactic allergy vaccination. Here we discuss recombinant allergy vaccines which are based on allergen-derived B cell epitopes regarding their molecular and immunological properties and review the results obtained in clinical studies with this new type of allergy vaccines.
|
|---|---|
| Authors | Rudolf Valenta, Raffaela Campana, Verena Niederberger |
| Journal | Immunology letters (Immunol Lett) Vol. 189 Pg. 19-26 (09 2017) ISSN: 1879-0542 [Electronic] Netherlands |
| PMID | 28472641 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't) |
| Copyright | Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved. |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!